Xandar Kardian offers the XK300 Autonomous Health Monitoring Solution, a commercially available, contact‑free, continuous vital sign monitoring (VSM) system that is FDA 510(k) cleared as a Class II medical device. The XK300 measures resting heart rate and respiratory rate autonomously, enabling patient monitoring and at‑home care. The company positions its measurements to be leveraged to predict health outcomes and enable more proactive provider interventions. Founded in 2017 as a U.S. Delaware C‑Corp, Xandar Kardian operates internationally across South Korea, Canada and the United States and is led by CEO and founder Sam Yang. The business intends to use new funding to continue expanding operations and to advance development efforts. The product and regulatory clearance indicate a commercially available clinical‑grade offering.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2021